Potential Autoimmunity of SARS CoV-2 Nucleic Acid-based Vaccination: What Should We Know?

Résumé

This preprint has been published: https://juniperpublishers.com/ijoprs/IJOPRS.MS.ID.555658.php mRNA based and adenovirus vectored vaccines, types of nucleic acid-based vaccination, were first ever or first commercially ever approved for the public, respectively. However, these new types possess a potential risk to induce auto-immune diseases more possibly in the short yet potentially the long term as well. On the other hand, all SARS CoV-2 types of vaccines, depending on the spike protein immunogenicity, including the conventional ones might increase the likelihood of COVID-19 severity upon re-infection through antibody dependent enhancement. Thus, a moral, legal, and constitutional public right to know and decide basing on a personalized risk benefit ratio must be secured. In this manuscript, we analyze the theoretical autoimmunity potential of SARS CoV-2 adenovirus vectored vaccines, after we have previously discussed the same potential for mRNA-based ones. Further, we explore the vulnerable groups of vaccines recipients who are generally more liable to develop autoimmune diseases and how might these groups modify the risk if decided to receive the vaccines.

Citer ce document

Accès au document

Ce document est hébergé sur son dépôt institutionnel d'origine.

Auteur(s)

Statistiques

Consultations : 1

Téléchargements : 0